Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 2/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPKAPK2 | P49137 | 4/20 | 0.35 |
| ▸ | RPS6KA2 | Q15349 | 2/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.32 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6958794 | 0.83 | HTR1A (0.48) | HTR1ADRD2MEN1KMT2ARAB9A | |
| SCHEMBL7971650 | 0.76 | HTR1A (0.35) | HTR1ADRD2MAPTTP53POLB | |
| SCHEMBL8100872 | 0.73 | HTR1A (0.35) | HTR1ADRD2MAPTTP53MAPKAPK2 | |
| SCHEMBL6958771 | 0.65 | HTR1A (0.50) | HTR1ADRD2MAPTTP53MEN1 | |
| SCHEMBL8110438 | 0.65 | ALDH1A1 (0.37) | HTR1ADRD2MAPTMAPKAPK2MEN1 | |
| SCHEMBL9336316 | 0.65 | HTR1A (0.58) | HTR1ADRD2MAPTTP53MEN1 | |
| SCHEMBL6960098 | 0.64 | ALDH1A1 (0.51) | HTR1ADRD2MAPTMEN1KMT2A | |
| SCHEMBL8114909 | 0.63 | HTR1A (0.38) | HTR1ADRD2MAPTTP53MEN1 | |
| Oxalic Acid SCHEMBL9334144 | 0.62 | HTR1A (0.56) | HTR1ADRD2MAPTTP53MEN1 | |
| SCHEMBL6965193 | 0.62 | HTR1A (0.56) | HTR1ADRD2MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125645-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | VALORISATION HSJ LP (CA) | 2026-05-07 | — | — | US | disclosed |
| WO-2024073845-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | VALORISATION HSJ, LIMITED PARTNERSHIP (CA) | 2024-04-11 | — | — | WO | disclosed |
| EP-0882726-B1 | Carbazol-carboxamides as 5-HT1F agonists | LILLY CO ELI (US) | 2003-05-21 | — | — | EP | disclosed |
| US-6221884-B1 | Carboxamides useful as 5-HT1F agonists | ELI LILLY AND COMPANY | 2001-04-24 | — | — | US | disclosed |
| WO-1998055115-A1 | CARBOXAMIDES USEFUL AS 5-HT1F AGONISTS | ELI LILLY AND COMPANY (US) | 1998-12-10 | — | — | WO | disclosed |
| EP-0882726-A1 | Carbazol-carboxamides as 5-HT1F agonists | ELI LILLY AND COMPANY (US) | 1998-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125645-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | HTR1F, HTR1A, HTR1D | HTR1A 2/4885DRD2 691/4885KDM1A 1567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.